COU-AA-301 Articles

Articles

#ASCO14 - Poster: Final analysis of a large, open-label global early access protocol with abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy

CHICAGO, IL USA (UroToday.com) - Presented by Cora N. Sternberg,¹ Gedske Daugaard,² Lajos Géczi,³ Sebastien J. Hotte,⁴ Paul N. Mainwaring,⁵ Fred Saad,⁶ Ciro Souza,⁷ Miah H. Tay,⁸ José M. Tello Garrido,⁹ Luca Galli,¹⁰ Anil Londhe,¹¹ Peter De Porre,¹² Dan Atlan,¹³ Betty Goon,¹¹ Emma Lee,¹² Tracy McGowan,¹¹ Vahid Naini,¹⁴ Mary B. Todd,¹⁵ Arturo Molina,¹⁶ and Daniel J. George¹⁷ at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

Published June 2, 2014
Abiraterone and increased survival in metastatic prostate cancer (from study COU-AA-301)

BERKELEY, CA (UroToday.com) - Men with progressive metastatic castration-resistant prostate cancer (mCRPC) often have a poor prognosis, and it is not until recent years that new treatment options have become available for these patients, treatments that prolong survival but are less toxic.
Published February 8, 2013
An overview of current and emerging therapeutic management strategies for patients with metastatic castration-resistant prostate cancer, "Beyond the Abstract," by Joelle El-Amm, MD and Jeanny Aragon-Ching, MD

BERKELEY, CA (UroToday.com) - The treatment of metastatic castrate resistant prostate cancer (mCRPC) has changed drastically over the past few years with the emergence of several new therapies.
Published July 12, 2013
ASCO 2013 - Podcast: CRPC: The place of novel agents focused on the androgen axis

CHICAGO, IL USA (UroToday.com) - Presented by William K. Oh, MD at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

Published June 10, 2013
ASCO 2013 - Slide Lecture: Effect of corticosteroid use at baseline on overall survival in patients receiving abiraterone acetate: Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer post-docetaxel

CHICAGO, IL USA (UroToday.com) - Presented by Bruce Montgomery,¹on behalf of Thian Kheoh,² Arturo Molina,² Jinhui Li,³ Joaquim Bellmunt,⁴ Charles J. Ryan,⁵ NamPhuong Tran,² Yohann Loriot,⁶ Eleni Efstathiou,⁷ Howard I. Scher,⁸ Johann S. de Bono⁹ at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

Published June 17, 2013
ASCO 2013 - Slide Presentation: CRPC: The place of novel agents focused on the androgen axis

CHICAGO, IL USA (UroToday.com) - Presented by William K. Oh, MD at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

Published June 10, 2013
EAU 2014 - Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate (AA) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials - Session Highlights

STOCKHOLM, SWEDEN (UroToday.com) - In this large multi-center study, authors retrospectively evaluated the efficacy outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) plus prednisone (P) vs P alone in pivotal studies COU-AA-301 (post-docetaxel) and COU-AA-302 (chemo-naïve), by Gleason score (≥ 8 or < 8), at initial diagnosis.
Published April 15, 2014
GU Cancers Symposium 2013 - Updated interim analysis (55% OS) of COU-AA-302, a randomized phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy - Slide Lecture

ORLANDO, FL, USA (UroToday.com) - Presented by Charles J. Ryan, MD, et al. at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA

Published April 5, 2013

COU-AA-301 Articles

Articles

Login